BRAF and melanoma: In addition, a study found that peroxisomal FAO (pFAO) in BRAF-mutated melanoma persister cells was up-regulated through the PPARα-PGC1α-ACOX1 axis, and the use of pFAO inhibitors combined with BRAF/MEK inhibitors to treat melanoma delayed the emergence of resistance to targeted therapy [130].